Research map: Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study

Back to the article

Papers in this map

  1. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor · Stephanie M. Bester · 2020 · 261 citations · Cited by this paper
  2. Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report · 2023 · Related
  3. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes · Nicolas Margot · 2020 · 69 citations · Cited by this paper
  4. Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine · 2025 · Related
  5. Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients · Anne‐Geneviève Marcelin · 2020 · 64 citations · Cited by this paper
  6. Analysis of risk factors and prediction model construction for varicella encephalitis in children: A retrospective cohort study · 2024 · Related
  7. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks · Rima K Acosta · 2019 · 60 citations · Cited by this paper
  8. Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation · 2023 · Related
  9. Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance · Annemarie M. J. Wensing · 2025 · 23 citations · Cited by this paper
  10. Andrographolide inhibits infectious bronchitis virus-induced apoptosis, pyroptosis, and inflammation · 2023 · Related
  11. HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018–2024 · Ron M. Kagan · 2025 · 15 citations · Cited by this paper
  12. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study · 2024 · Related
  13. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1) · Karam Mounzer · 2024 · 12 citations · Cited by this paper
  14. Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection · 2024 · Related
  15. Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting · Charlotte-Paige Rolle · 2020 · 11 citations · Cited by this paper
  16. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA · 2023 · Related
  17. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting · Huimin Chang · 2022 · 9 citations · Cited by this paper
  18. Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV · 2022 · Related
  19. Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial · Chloe Orkin · 2026 · 4 citations · Cited by this paper
  20. Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study · 2024 · Related
  21. Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study · Nina Pennetzdorfer · 2026 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)